Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Declines By 14.6%

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a decline of 14.6% from the February 13th total of 1,850,000 shares. Based on an average trading volume of 783,000 shares, the short-interest ratio is presently 2.0 days. Approximately 4.7% of the shares of the stock are short sold.

Institutional Investors Weigh In On Iterum Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Lee Financial Co bought a new stake in Iterum Therapeutics in the fourth quarter worth $28,000. Sanctuary Advisors LLC bought a new position in shares of Iterum Therapeutics during the fourth quarter valued at approximately $35,000. Citadel Advisors LLC bought a new stake in shares of Iterum Therapeutics during the fourth quarter valued at approximately $38,000. Two Sigma Investments LP purchased a new stake in Iterum Therapeutics in the fourth quarter worth approximately $45,000. Finally, Apollon Financial LLC boosted its stake in shares of Iterum Therapeutics by 11.3% during the 4th quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock worth $443,000 after acquiring an additional 25,500 shares during the last quarter. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Trading Up 5.8 %

Shares of ITRM traded up $0.08 during midday trading on Wednesday, reaching $1.46. The stock had a trading volume of 332,746 shares, compared to its average volume of 959,690. The company has a market capitalization of $50.32 million, a price-to-earnings ratio of -1.11 and a beta of 2.44. Iterum Therapeutics has a 12-month low of $0.81 and a 12-month high of $3.02. The company’s 50-day moving average is $1.48 and its 200 day moving average is $1.48.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.